Home › Trial NCT04348643
Safety and Efficacy of CEA-Targeted CAR-T Therapy for Relapsed/Refractory CEA+ Cancer
- Trial IDNCT04348643
- StatusWithdrawn
- PhasePhase 1/2
- Study typeInterventional
- SponsorChongqing Precision Biotech Co., Ltd
- Enrollment—
- Start date2020-02-20
- ConditionsSolid Tumor · Lung Cancer · Colorectal Cancer · Liver Cancer · Pancreatic Cancer · Gastric Cancer
Enriched analysis
Parsed endpoints, structured eligibility, drug class and a plain-English summary — shown to verified visitors to prevent automated scraping.
Human verification coming soon — the enriched analysis will be viewable here.
Trial data from ClinicalTrials.gov (U.S. public domain) and ISRCTN (CC BY 4.0), used with attribution. TrialLens is an independent index, not affiliated with or endorsed by ClinicalTrials.gov, the NIH, or any trial sponsor. For research only — not medical advice.